NBDF showcases a wide array of findings from the latest in bleeding disorders research at our annual Bleeding Disorders Conference.
Pharmacokinetics and Prophylaxis Regimens and Relationship to Bleed Outcomes in Patients With Severe Hemophilia A Treated with BAY 81-8973
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
Biomedical/Coagulation Research
Management of Hemophilia B in US Women and Its Impact on Education, Employment, and Activities: Results From the Bridging Hemophilia B Experiences, Results, and Opportunities Into Solutions (B-HERO-S) Study
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
Psychosocial Issues
Updated results from a dose-escalation study in adults with severe or moderate-severe hemophilia B treated with AMT-060 (AAV5-hFIX) gene therapy: up to 1.5 years follow-up
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
Clinical Research/Clinical Trials
Lessons Learned in the Assessment of Functional Status in US Adults With Hemophilia in the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study: Importance of More Formalized Assessment of Function in the Comprehensive Care Setting
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
Quality of Life/Outcomes Research
A Feasibility and Usability Study of a Nursing Orchestrated, Customized 3 Dimensional Virtual Reality Environment in Children with Hemophilia Undergoing Routine Intravenous Procedures
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
Clinical Research/Clinical Trials
Estimating the prevalence of symptomatic, undiagnosed von Willebrand disease: analysis of medical insurance claims data
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
Clinical Research/Clinical Trials
Ethics of Compensated Plasma Donation
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
Law/Ethics/Health Policy
Efficacy, safety and pharmacokinetics of emicizumab (ACE910) prophylaxis in persons with hemophilia A with inhibitors: randomized, multicenter, open-label, phase 3 study (HAVEN 1)
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
Clinical Research/Clinical Trials
Depression levels in patients with Hemophilia and von Willebrand
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
Psychosocial Issues
Qualitative findings from bleeding disorders camp
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
Psychosocial Issues
Hereditary factor X (FX) deficiency in women and girls: treatment with a high purity plasma-derived factor X concentrate
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
Clinical Research/Clinical Trials
Management of Hemophilia Carriers Around The Time of Their Delivery: Phenotypic Variation Requiring Customization of Management
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
Women's Research
Centralized Inhibitor Testing in the United States: Laboratory Methods Used for the Community Counts Registry for Bleeding Disorders Surveillance
AWARDED/PRESENTED: 2017
GRANT/PROGRAM:
Bleeding Disorders Conference
Inhibitors
Quantitative research into people with hemophilia and caregiver perceptions of pre-filled solvent syringe (MixPro®)
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
New Products
Personalization of Treatment Regimens for Physically Active Patients: A Comparison of Factor VIII and Extended Half-life Treatment Regimens
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
New Products
Pharmacist/Provider Collaboration needed to Optimize Dosing Regimens in Order to Reduce Bleed Rates in Hemophilia A Patients on Prophylaxis Regimens
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
Collaboration/Team Models
Cost of Treating Thrombotic Events in a US Population of Von Willebrand Disease Patients
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
Biomedical/Coagulation Research
Interim results of the B-YOND study evaluating long-term safety and efficacy of recombinant factor IX Fc (rFIXFc) in children with severe hemophilia B
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
Clinical Research/Clinical Trials
The impact of missing one or two infusions per month: a comparison of rFVIII and rFVIIIFc regimens
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
Quality of Life/Outcomes Research
SPINART 3-Year Analyses: Patient- and Joint-Level Changes in Colorado Adult Joint Assessment Scale and Magnetic Resonance Imaging Scores With Bayer’s Sucrose-Formulated Recombinant Factor VIII (rFVIII-FS) in Adolescents and Adults
AWARDED/PRESENTED: 2015
GRANT/PROGRAM:
Bleeding Disorders Conference
Clinical Research/Clinical Trials